These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 8239515)

  • 1. In vivo use of N-(4-hydroxyphenyl retinamide)-0-glucuronide as a breast cancer chemopreventive agent.
    Abou-Issa H; Curley RW; Panigot MJ; Wilcox KA; Webb TE
    Anticancer Res; 1993; 13(5A):1431-6. PubMed ID: 8239515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapeutic evaluation of N-(4-hydroxyphenyl) retinamide-O-glucuronide in the rat mammary tumor model.
    Abou-Issa H; Curley RW; Panigot MJ; Tanagho SN; Sidhu BS; Alshafie GA
    Anticancer Res; 1997; 17(5A):3335-9. PubMed ID: 9413168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemopreventive activity of a C-glucuronide analog of N-(4-hydroxyphenyl) retinamide-O-glucuronide against mammary tumor development and growth.
    Abou-Issa HM; Alshafie GA; Curley RW; Wong MF; Clagett-Dame M; Repa JJ; Sikri V
    Anticancer Res; 1999; 19(2A):999-1004. PubMed ID: 10368645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemopreventive activities of C-glucuronide/glycoside analogs of retinoid-O-glucuronides against breast cancer development and growth.
    Curley RW; Abou-Issa H; Panigot MJ; Repa JJ; Clagett-Dame M; Alshafie G
    Anticancer Res; 1996; 16(2):757-63. PubMed ID: 8687125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapeutic evaluation of 4-hydroxybenzylretinone (4-HBR), a nonhydrolyzable C-linked analog of N-(4-hydroxyphenyl) retinamide (4-HPR) against mammary carcinogenesis.
    Abou-Issa H; Curley RW; Alshafie GA; Weiss KL; Clagett-Dame M; Chapman JS; Mershon SM
    Anticancer Res; 2001; 21(6A):3839-44. PubMed ID: 11911255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of short-term administration of N-(4-hydroxyphenyl)-all-trans-retinamide on chemically induced mammary tumors.
    Silverman J; Katayama S; Radok P; Levenstein MJ; Weisburger JH
    Nutr Cancer; 1983; 4(3):186-91. PubMed ID: 6221232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative chemopreventive activity of ibuprofen and N-(4-hydroxyphenyl) retinamide against the development and growth of rat mammary adenocarcinomas.
    Alshafie GA; Harris RE; Robertson FM; Parrett ML; Ross M; Abou-Issa H
    Anticancer Res; 1999; 19(4B):3031-6. PubMed ID: 10652588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of mammary tumor growth by a novel nontoxic retinoid: chemotherapeutic evaluation of a C-linked analog of 4-HPR-glucuronide.
    Alshafie GA; Walker JR; Curley RW; Clagett-Dame M; Highland MA; Nieves NJ; Stonerock LA; Abou-Issa H
    Anticancer Res; 2005; 25(3c):2391-8. PubMed ID: 16082771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative efficacy of glucarate on the initiation and promotion phases of rat mammary carcinogenesis.
    Abou-Issa H; Moeschberger M; el-Masry W; Tejwani S; Curley RW; Webb TE
    Anticancer Res; 1995; 15(3):805-10. PubMed ID: 7645962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced inhibition of mammary carcinogenesis by combined treatment with N-(4-hydroxyphenyl)retinamide and ovariectomy.
    McCormick DL; Mehta RG; Thompson CA; Dinger N; Caldwell JA; Moon RC
    Cancer Res; 1982 Feb; 42(2):508-12. PubMed ID: 6459843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer chemopreventive activity mediated by deguelin, a naturally occurring rotenoid.
    Udeani GO; Gerhauser C; Thomas CF; Moon RC; Kosmeder JW; Kinghorn AD; Moriarty RM; Pezzuto JM
    Cancer Res; 1997 Aug; 57(16):3424-8. PubMed ID: 9270008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative ability of ibuprofen and N-(4-hydroxyphenyl)retinamide to inhibit development of rat mammary adenocarcinomas associated with differential inhibition of gene expression of cyclooxygenase isoforms.
    Parrett ML; Abou-Issa HM; Alshafie G; Ross MS; Harris RE; Robertson FM
    Anticancer Res; 1999; 19(6B):5079-85. PubMed ID: 10697514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sulfone metabolite of sulindac inhibits mammary carcinogenesis.
    Thompson HJ; Jiang C; Lu J; Mehta RG; Piazza GA; Paranka NS; Pamukcu R; Ahnen DJ
    Cancer Res; 1997 Jan; 57(2):267-71. PubMed ID: 9000566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Putative metabolites derived from dietary combinations of calcium glucarate and N-(4-hydroxyphenyl)retinamide act synergistically to inhibit the induction of rat mammary tumors by 7,12-dimethylbenz[a]anthracene.
    Abou-Issa HM; Duruibe VA; Minton JP; Larroya S; Dwivedi C; Webb TE
    Proc Natl Acad Sci U S A; 1988 Jun; 85(12):4181-4. PubMed ID: 2967969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of lycopene-enriched tomato oleoresin on 7,12-dimethyl-benz[a]anthracene-induced rat mammary tumors.
    Sharoni Y; Giron E; Rise M; Levy J
    Cancer Detect Prev; 1997; 21(2):118-23. PubMed ID: 9101071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-response effects of the COX-2 inhibitor, celecoxib, on the chemoprevention of mammary carcinogenesis.
    Abou-Issa HM; Alshafie GA; Seibert K; Koki AT; Masferrer JL; Harris RE
    Anticancer Res; 2001; 21(5):3425-32. PubMed ID: 11848504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Purple grape juice inhibits 7,12-dimethylbenz[a]anthracene (DMBA)-induced rat mammary tumorigenesis and in vivo DMBA-DNA adduct formation.
    Jung KJ; Wallig MA; Singletary KW
    Cancer Lett; 2006 Feb; 233(2):279-88. PubMed ID: 15878797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemopreventive efficacy of combined retinoid and tamoxifen treatment following surgical excision of a primary mammary cancer in female rats.
    Ratko TA; Detrisac CJ; Dinger NM; Thomas CF; Kelloff GJ; Moon RC
    Cancer Res; 1989 Aug; 49(16):4472-6. PubMed ID: 2525951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retinoid receptor-dependent and independent biological activities of novel fenretinide analogues and metabolites.
    Sabichi AL; Xu H; Fischer S; Zou C; Yang X; Steele VE; Kelloff GJ; Lotan R; Clifford JL
    Clin Cancer Res; 2003 Oct; 9(12):4606-13. PubMed ID: 14555536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth suppression of human breast carcinoma cells in culture by N-(4-hydroxyphenyl)retinamide and its glucuronide and through synergism with glucarate.
    Bhatnagar R; Abou-Issa H; Curley RW; Koolemans-Beynen A; Moeschberger ML; Webb TE
    Biochem Pharmacol; 1991 May; 41(10):1471-7. PubMed ID: 1826840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.